Advertisement

Treatment of Paget’s Disease with the New Bisphosphonates

  • John A. Kanis
  • Eugene V. McCloskey
  • Declan O’Doherty
  • Neveen A. T. Hamdy
  • Derek Bickerstaff
  • Monique Beneton
  • Maniccam Thavarajah

Abstract

The increased availability of the bisphosphonates over the past 15 years has revolutionized the medical treatment of Paget’s disease and also stimulated renewed interest in its surgical management. Etidronate is the most widely available bisphosphonate, and it is against a wide experience of this agent that new bisphosphonates are being evaluated.

Keywords

Inhibit Bone Resorption Bone Blood Flow Pagetic Bone Spinal Cord Dysfunction Etidronate Disodium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gray RES, Yates AJP, Preston CJ, et al: Duration of effect of oral diphosphonate therapy in Paget’s disease of bone. Q J Med 1987; 64: 755–767.PubMedGoogle Scholar
  2. 2.
    Russell RGG, Smith R, Preston C, et al: Diphosphonates in Paget’s disease. Lancet 1974; 1: 894–898.PubMedGoogle Scholar
  3. 3.
    Canfield R, Rosner W, Skinner J, et al: Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 1977; 44: 96–106.PubMedCrossRefGoogle Scholar
  4. 4.
    Siris ES, Canfield RE, Jacobs TE, et al: Long-term therapy of Paget’s disease of bone with EHDP. Arthritis Rheum 1980; 23: 1177–1183.PubMedCrossRefGoogle Scholar
  5. 5.
    Preston CJ, Yates AJP, Beneton MNC, et al: Effective short term treatment of Paget’s disease with oral etidronate. Br Med J 1986; 292: 79–80.CrossRefGoogle Scholar
  6. 6.
    Kanis JA, Urwin GH, Gray RES, et al: Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 1987; 82 (suppl 2A): 55–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Fleisch H: Experimental basis for the use of bisphosphonates in Paget’s disease of bone. Clin Orthop 1987; 217: 72–78.PubMedGoogle Scholar
  8. 8.
    Fleisch H: Bisphosphonates: Mechanisms of action and clinical applications, in Peck WA (ed): Bone and Mineral Research Annual 1. Amsterdam, Excerpta Medica, 1989; pp 319–357.Google Scholar
  9. 9.
    Shinoda H, Adamek G, Felix R, et al: Structure-activity relationship of various bisphosphonates. Calcif Tissue Int 1983; 35: 87–99.PubMedCrossRefGoogle Scholar
  10. 10.
    Yakatan GL, Poynor WJ, Talbert RL, et al: Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982, 31: 402–410.PubMedCrossRefGoogle Scholar
  11. 11.
    Fogelman I, Smith L, Mazess R, et al: Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24: 57–62.CrossRefGoogle Scholar
  12. 12.
    Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ: Efficacious management with aminobisphophonate (APD) in Paget’s disease of bone. Clin Orthop 1987; 217: 79–98.PubMedGoogle Scholar
  13. 13.
    Michael WR, Kjfiìg WR, Wakim JM: Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog, and monkey. Toxicol Appl Pharmacol 1972; 21: 503–515.PubMedCrossRefGoogle Scholar
  14. 14.
    Yates AJP, Percival RC, Gray RES, et al: Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1985; 1: 474 - 477.Google Scholar
  15. 15.
    Atkins RM, Yates AJP, Gray RES, et al: Aminohexane disphosphonate in the treatment of Paget’s disease of bone. J Bone Mineral Res 1987; 2: 273 - 279.CrossRefGoogle Scholar
  16. 16.
    O’Docherty DP, Bickerstaff DR, McCloskey EV, et al: The treatment of Paget’s disease with aminobutylidene diphosphonate. J Bone Mineral Res In Press.Google Scholar
  17. 17.
    Delmas PD, Chapuy MC, Vignon E, et al: Long-term effects of dichloromethylene diphosphonate in Paget’s disease of bone. J Clin Endocrinol Metab 1982; 54: 837 - 844.PubMedCrossRefGoogle Scholar
  18. 18.
    Meunier PJ, Saison C, Mathieu L, et al: Skeletal distribution of Paget’s disease. Clin Orthop 1987; 217: 37 - 44.PubMedGoogle Scholar
  19. 19.
    Douglas DL, Duckworth T, Kanis JA, et al: Biochemical and clinical response to dichloromethylene diphosphonate (G2MDP) in Paget’s disease of bone. Arthritis Rheum 1980; 23: 1185 - 1192.PubMedCrossRefGoogle Scholar
  20. 20.
    Meunier PJ, Alexandre C, Edouard C, et al: Effects of disodium dichloromethylene diphosphonate on Paget’s disease of bone. Lancet 1979; 2: 489–492.PubMedCrossRefGoogle Scholar
  21. 21.
    Espinasse D, Mathieu L, Alexandre C, et al: The kinetics of 99mTc labelled EHDP in Paget’s disease before and after dichloromethylene-diphosphonate treatment. Metab Bone Dis 1981; 2: 321 - 324.CrossRefGoogle Scholar
  22. 22.
    Chapuy MC, Charon SA, Meunier PJ: Sustained biochemical effects of short treatment of Paget’s disease of bone with dichloromethylene diphosphonate. Metab Bone Dis 1983; 4: 325–328.Google Scholar
  23. 23.
    McCloskey EV, Yates AJP, Beneton MNC, et al: Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8 (suppl 1): 35–42.Google Scholar
  24. 24.
    Douglas DL, Duckworth T, Kanis JA, et al: Spinal cord dysfunction in Paget’s disease of bone: Has medical treatment a vascular basis? J Bone Joint Surg 1981;63-B:495–503.Google Scholar
  25. 25.
    Borgstrom GH, Elomaa I, Blomqvist C, Porkka L: Cytogenetic investigations of patients on clodronate therapy for Paget’s disease of bone. Bone 1987; 8 (suppl l): 85–86.Google Scholar
  26. 26.
    Reginster JY, Lecart MP, Deroisy R, et al: Treatment of Paget’s disease of bone with high oral doses of oral tiludronate given during a five-day course therapy. J Bone Mineral Res 1990; 5 (suppl 2): 170.Google Scholar
  27. 27.
    Papapoulos SE, Frolisch M, Hoekman K, Bijvoet OLM: Dimethyl-APD treatment modifies osteoblastic function in patients with Paget’s disease. Calcif Tissue Int 1989; 44(suppl):sl08.Google Scholar
  28. 28.
    Reginster JY, Jeugmans-Huynen AM, Albert A, et al: One year’s treatment of Paget’s disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Mineral Res 1988; 3: 249–252.CrossRefGoogle Scholar
  29. 29.
    Kanis JA, Heynen G, Paterson A, et al: Endogenous secretion of calcitonin in physiological and pathological conditions, in Pecile A (ed): Calcitonin. Amsterdam, Elsevier, 1985, pp 81–88.Google Scholar
  30. 30.
    Kanis JA, Gray RES, McCloskey EV: Treating Paget’s disease. Br Med J 1987; 294: 1612–1613CrossRefGoogle Scholar
  31. 31.
    Elomaa I, Blomqvist C, Grohn P, et al: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; 1: 146–149.PubMedCrossRefGoogle Scholar
  32. 32.
    Siris ES, Hyman GA, Canfield RE: Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983; 74: 401.PubMedCrossRefGoogle Scholar
  33. 33.
    Dove J: Complete fractures of the femur in Paget’s disease of bone. J Bone Joint Surg 1980; 62B: 12–17.Google Scholar
  34. 34.
    Bowie HIC, Kanis JA: Calcitonin in the assessment and preparation of patients with Paget’s disease for surgery, in Kanis JA (ed): Bone Disease and Calcitonin. Eastbourne, England, Armour Pharmaceutical, 1977, pp 61–69.Google Scholar
  35. 35.
    Doyle FH, Banks LM, Pennock JM: Radiologic observations on bone resorption in Paget’s disease. Arthritis Rheum 1980; 23: 1205–1214.PubMedCrossRefGoogle Scholar
  36. 36.
    Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, et at: Treatment of Paget’s disease with the diphosphonate APD: A biological and radiological study, in Donath A, Courvoisier B (eds): Diphosphonates and Bone. Geneva, Editions Medicine et Hygiene, 1982, pp 303–327.Google Scholar
  37. 37.
    Altman RD: Long-term follow up of therapy with intermittent etidronate disodium in Paget’s disease of bone. Am J Med 1985; 79: 583–590.PubMedCrossRefGoogle Scholar
  38. 38.
    Bickerstaff D, Douglas DL, Burke PH, et al: Improvement in facial deformity of Paget’s disease treated with diphosphonates. J Bone Joint Surg 1990; 728: 132–136.Google Scholar
  39. 39.
    Douglas DL, Ranis JA, Duckworth T, et al: Paget’s disease: Improvement of spinal cord dysfunction with diphosphonates and calcitonin. Metab Bone Dis 1981; 3: 327–336.CrossRefGoogle Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • John A. Kanis
  • Eugene V. McCloskey
  • Declan O’Doherty
  • Neveen A. T. Hamdy
  • Derek Bickerstaff
  • Monique Beneton
  • Maniccam Thavarajah

There are no affiliations available

Personalised recommendations